Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.16 (calcineurin)
 17,112 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The present work has examined the effects of okadaic acid, an inhibitor of serine/threonine protein phosphatase, PP-1 and PP-2A, on the regulation of EGR-1 gene expression in normal peripheral blood T- and Jurkat cells. The results demonstrate that okadaic acid treatment is associated with a transient induction of EGR-1 gene expression which was detectable by 30 min to 1 h and peaked at 3-6 h. EGR-1 mRNA was superinduced in cells treated with both okadaic acid and the protein synthesis inhibitor cycloheximide. The half-life of EGR-1 mRNA was similar in both control and okadaic acid-treated cells. In contrast, treatment with both okadaic acid and cycloheximide prolonged the half-life of EGR-1 transcripts. Nuclear run-on assays demonstrated that induction of EGR-1 gene expression by okadaic acid is controlled at least in part by a transcriptional mechanism. Transient expression assays with EGR-1 promotor fragments linked to the chloramphenicol acetyltransferase gene demonstrate that okadaic acid-induced EGR-1 transcription is conferred by the 5' most distal CArG box, CC (AT)6GG, in the EGR-1 promoter. Moreover, chloramphenicol acetyltransferase activity was induced by okadaic acid when the 5' most distal CArG element was linked to the heterologous herpes simplex virus thymidine kinase promoter, and not induced with a similar heterologous construct containing a mutated CArG sequence. These studies demonstrate that okadaic acid regulates EGR-1 gene expression at the transcriptional level via the CArG element and suggest that PP-1 and PP-2A play a role in T-cell activation.
Cancer Res 1994 Apr 15
PMID:Involvement of serum response element in okadaic acid-induced EGR-1 transcription in human T-cells. 817 32

Elevated cyclic AMP levels induce a rapid block in the mid-G1 phase of the cell cycle in B-lymphoid Reh cells, accompanied by a transient block in G2. The retinoblastoma (Rb) gene product has been implicated as a key regulator of eukaryotic cell growth. The Rb protein enforces its growth-suppressive effect in early G1, where it is underphosphorylated and firmly bound in the nucleus. A possible link between the cyclic AMP-mediated growth arrest and regulation of Rb protein phosphorylation was explored by Western blot analysis. We found that both forskolin and 8-(4-chlorophenylthio)adenosine 3':5'-cyclic monophosphate induced a rapid (within 3 h) dephosphorylation of Rb protein. These data were confirmed by flow-cytometric analysis of isolated nuclei costained with anti-Rb antibodies and propidium iodide. The percentage of cells containing underphosphorylated Rb protein (i.e., G1 nuclei with bound Rb protein) increased from 9 to 87% after 4 h of forskolin treatment. During the first 4 h of forskolin treatment, the cells were transiently blocked in the G2 phase of the cell cycle, and virtually no cells had passed through mitosis. The increased level of dephosphorylated Rb protein at 4 h was therefore not due to an accumulation in early G1 of cells containing underphosphorylated Rb protein. Instead, our data indicated that dephosphorylation of Rb protein occurred in cells that had already passed the point in G1 of Rb protein phosphorylation. Dephosphorylation of Rb protein was prevented by high concentrations of the protein phosphatase inhibitor okadaic acid, indicating that activation of a phosphatase is involved in the cyclic AMP-mediated dephosphorylation of Rb protein. We suggest that the dephosphorylation of Rb protein is required for the forskolin-mediated arrest of the Reh cells in mid-G1.
Cancer Res 1994 Apr 15
PMID:Retinoblastoma protein is rapidly dephosphorylated by elevated cyclic adenosine monophosphate levels in human B-lymphoid cells. 817 34

Suramin has long been used for the treatment of Gambian and Rhodesian trypanosomiasis and oncocerciasis. More recently, the demonstration that suramin inhibits DNA polymerases, reverse transcriptase and the lymphocyte terminal deoxynucleotidyl transferase has led to its clinical trials for the treatment of AIDS and cancer. The precise nature of suramin's anti-neoplastic action is not clear at this time. Suramin rapidly alters the tyrosine-specific phosphorylation of cellular proteins in many cancer cell lines. Here we demonstrate that suramin strongly inhibits the activity of CD45, the principal tyrosine specific protein phosphatase of T lymphocytes. Suramin-induced inactivation of CD45 is noncompetitive, irreversible and complete within 10 min. The ability of suramin to block CD45 mediated phosphatase function provides both new insight into the mechanism of action of this agent and a useful new probe for studies of T cell activation.
 ...
PMID:Suramin, an experimental chemotherapeutic drug, irreversibly blocks T cell CD45-protein tyrosine phosphatase in vitro. 833 52

In these studies, Syrian hamster embryo cells (SHE), which were isolated at different stages of neoplastic progression, were used to test the ability of the protein phosphatase inhibitors, okadaic acid and sodium orthovanadate (Na3VO4) to induce neoplastic progression. We observed that these chemicals can induce transition of the cells from one stage to the other at different points in the multistep process of neoplastic transformation. Three steps in this multistep process were studied: escape from cellular senescence, loss of a tumor suppressor gene function in immortal cells, and aquisition of anchorage-independent growth. Treatment of normal, primary SHE cells with okadaic acid or Na3VO4 allowed the cells to escape senescence and become immortal at a low frequency. The induction of immortality was associated with nonrandom chromosome changes, including trisomy 8 and 11 and monosomy 13 and Xq. The transition of preneoplastic cells to more advanced stages was also studied in immortal, nontumorigenic cells that either have retained (supB+) or have lost (supB-) the ability to suppress tumorigenicity of a transformed cell line in cell hybrids. SupB+ and supB- cells do not normally grow in agar, but supB- cells will grow in agar if additional growth factors are added. However, upon addition of protein phosphatase inhibitors, supB+ cells exhibited the supB- phenotype; for example, colony formation of supB+ cells was observed in agar supplemented with growth factors and protein phosphatase inhibitors. Following treatment, selection of these colonies showed that 89% of these cells heritably acquired the phenotype of cells that have lost the suppressor gene function (supB-). SupB- cells were also treated with protein phosphatase inhibitors in soft agar in the presence of additional growth factors. While the frequency of colonies in agar supplemented with growth factors in agar was not greatly enhanced, approximately 50% of the colonies acquired the ability to grow in agar autonomously without the supplemented growth factors, similar to tumorigenic cells. These studies suggest that Na3VO4 and okadaic acid induce progression of cells through various stages in this multistep system.
Cancer Res 1993 Apr 15
PMID:Induction of neoplastic progression in Syrian hamster embryo cells treated with protein phosphatase inhibitors. 838 70

Four distinct cDNAs for rat protein phosphatase-1 have been isolated from rat tissues (Sasaki et al., Jpn. J. Cancer Res. 81, 1272-1280, 1990). These cDNAs encode proteins of highly similar sequence, the major differences being located at their N and C termini. In order to demonstrate that these cDNAs encode functional proteins and to investigate their enzymatic properties, it would be desirable to obtain purified preparations of these proteins. Using a system that was developed for the expression of rabbit muscle protein phosphatase-1 (Zhang et al., J. Biol. Chem. 267, 1484-1490, 1992) we have expressed these isoforms in Escherichia coli. The four recombinant isoforms were purified to near homogeneity and their properties were examined in terms of substrate specificity and sensitivity to okadaic acid and inhibitor-2.
 ...
PMID:Expression and characterization of rat protein phosphatases-1 alpha, -1 gamma 1, -1 gamma 2, and -1 delta. 839 Feb 22

We investigated the effect of protein kinase and phosphatase inhibitors on the growth of six human prostatic cancer cell lines: DU145, PC3, ND1, LNCaP, ALVA31 and JCA1. We studied okadaic acid and sodium orthovanadate as serine/threonine and tyrosine protein phosphatase inhibitors, respectively, and staurosporin and genistein as a serine/threonine and tyrosine protein kinase inhibitors, respectively. All inhibitors examined exhibited a dose-dependent growth inhibitory effect on prostatic cancer cell lines. Our data indicate that prostatic cancer cell lines express unique biochemical properties since the degree of growth inhibition varied greatly and was dependent on the specific cell line and inhibitor studied. In addition, we found that surface expression of endoglin (CD105) changed by treatment with all inhibitors in most of the cell lines. These data also indicate that endoglin appears to be involved both in protein phosphatase and kinase mediated phosphoprotein turnover.
Cancer Lett 1995 Nov 27
PMID:Differential sensitivity of human prostatic cancer cell lines to the effects of protein kinase and phosphatase inhibitors. 852 97

The last several years has seen an explosion in the identification of a multiplicity of serine/threonine protein kinases with important functions in eukaryotic cell cycle progression. Although the major serine/threonine phosphoprotein phosphatases, that must oppose the action of the kinases, have been identified and extensively characterized for their involvement in metabolic processes, the functions of the phosphatases in cell cycle regulation is less well established. This paper focuses on the role of the type-2A protein phosphatase (PP2A) in the regulation of the G2/M transition in the Xenopus cell cycle. Although a role for PP2A in regulating G2/M has been suggested by studies in various systems, it is the relative simplicity of the in-vitro cell cycle extracts of Xenopus that has allowed the clearest dissection of the mechanism by which PP2A regulates this transition.
Semin Cancer Biol 1995 Aug
PMID:The role of protein phosphatase type-2A in the Xenopus cell cycle: initiation of the G2/M transition. 854 15

Research conducted over the last decade has provided a wealth of new information on the molecular mechanisms utilized by DNA tumour viruses. Studies of tumour viruses have led to important insights into the functions of viral proteins and into the regulation of normal cellular proliferation. DNA tumour viruses can stimulate growth factor signaling pathways, alter gene transcription, and inactivate growth suppressor proteins. Members of the polyoma and adenovirus families express proteins that interact with protein serine/threonine phosphatase 2A (PP2A). In the case of SV40 virus, this interaction plays an accessory role in transformation of most cells, while it is essential for transformation of some cell types. The topics discussed in this review include the interactions of these viral proteins with PP2A, the effects of these interactions on phosphatase activity, and how these interactions alter cellular signal transduction pathways.
Semin Cancer Biol 1995 Aug
PMID:Regulation by tumour antigens defines a role for PP2A in signal transduction. 854 18

The molecular cloning of protein phosphatase 2A subunits from Drosophila has provided insights into the role this enzyme plays in developmental processes and in cell cycle regulation. The trimeric holoenzyme containing the catalytic, 65-kDa and 55-kDa regulatory subunits appears to be preferentially expressed in proliferative organs such as the gonads, in the developing nervous system and in early syncytial embryos. Analysis of mutant flies affected in the expression of the 55-kDa regulatory subunit suggests that the holoenzyme containing this subunit plays a pivotal role in cell cycle regulation and cell fate determination. The severity of the mutant phenotype correlates with a decrease in 55-kDa subunit protein levels and reduced protein phosphatase activity towards p34cdc2 phosphorylated proteins. The data support the idea that the 'variable' subunits of protein phosphatase 2A holoenzymes play a critical role in directing substrate specificity.
Semin Cancer Biol 1995 Aug
PMID:Role of protein phosphatase 2A in Drosophila development. 854 20

Cellular insensitivity to vinca alkaloids is suggested to be primarily due to drug efflux by P-glycoprotein (P-gp). The anti-epileptic phenytoin (DPH), which does not bind to P-gp, can selectively enhance vincristine (VCR) cytotoxicity in wild-type (WT) or multidrug-resistant (MDR) cells. We now demonstrate that the protein phosphatase inhibitor okadaic acid (OKA) can mimic the effect of DPH by selectively enhancing cytotoxicity of vinblastine (VBL), but not taxol and doxorubicin, in human leukaemia HL-60 cells. Both DPH and OKA potentiate the anti-mitotic effects of VBL by enhanced damage to the mitotic spindle, resulting in prolonged growth arrest. Also, unlike VBL alone, in human leukaemia or non-small-cell lung carcinoma cells treated with VBL plus DPH, recovery from damage to the mitotic spindle is compromised in drug-free medium and cell death by apoptosis in interphase ensues. Since protein phosphatases are involved with the regulation of metaphase to anaphase transit of cells during the mitotic cycle, enhanced VBL cytotoxicity in the presence of DPH or OKA may involve effects during metaphase on the mitotic spindle tubulin leading to growth arrest and apoptosis in interphase. These novel results suggest that DPH or OKA could be powerful tools to study cellular effects of vinca alkaloids and possibly for the development of novel therapeutic strategies.
Br J Cancer 1996 Jan
PMID:Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells. 854 4


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>